expects to launch new allergy tablet in U.S. in 2017
Send a link to a friend
[March 20, 2014]
COPENHAGEN (Reuters) —
Danish pharmaceutical group Alk Abello expects to start selling its
new dust mite allergy tablet in Europe and Japan around the end 2015
with the U.S. market a further year behind, its Chief Executive told
Reuters on Thursday.
The HDM SLIT-tablet, which just entered third phase
in the development program in North America, could be the most
important of three allergy tablets the company is developing in
association with American healthcare company Merck, Alk's Chief
Executive Jens Bager said in an interview.
"It is the treatment in which we see both the biggest commercial and
economic potential," Bager said.
"House dust mite-allergy is one of the most debilitating allergies
and is often associated with allergic asthma and affects more than
30 million Americans."
He said that studies in Europe and Japan show Alk's HDM SLIT-tablet
is able to reduce dust mite allergy symptoms significantly, adding
that there were few rival medicines on the market.
[to top of second column]
Alk expects royalties of about 15-20 percent of sales of the three
treatments being developed with Merck. The two firms are developing
tablets are for pollen and grass allergies as well as the dust mite
(Reporting by Annabella Pultz Nielsen;
editing by Simon Johnson)
[© 2014 Thomson Reuters. All rights
Copyright 2014 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.